Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends
Soligenix reported a Q3 net loss of $2.5 million, widening due to increased clinical trial expenses, with no revenue reported for both Q3 2025 and Q3 2024. The company has $10.5 million in cash, ensuring operations through 2026, and is exploring partnerships to advance its pipeline. Analysts maintain a 'buy' rating, with a median 12-month price target of $17.50, reflecting a potential 92.7% increase from its recent closing price of $1.28.
)
Overview
- Soligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expenses
- Company reports no revenue for Q3 2025, same as Q3 2024
- Soligenix has $10.5 mln cash, providing runway through 2026
Outlook
- Soligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026
- Company plans to carefully allocate resources to achieve strategic goals
- Soligenix exploring partnerships and financing to advance late-stage pipeline
Result Drivers
- CLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trial
- CASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding options
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$2.50
Income mln
Analyst Coverage
- The one available analyst rating on the shares is “buy”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Soligenix Inc is $17.50, about 92.7% above its November 6 closing price of $1.28
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
